Commodore Capital is a venture capital firm that primarily focuses on long-term growth opportunities within the healthcare and biopharmaceutical sectors. They employ a science-driven investment strategy, targeting early-stage, small-cap public, and late-stage private companies that are developing innovative medical products, with an emphasis on scientific breakthroughs, genetic medicines, and cellular therapies.
100% of their portfolio is in Biotech & Life Sciences. They made 2 investments in the last 12 months. Their most common stage is series-b (50% of deals). Average disclosed round size is $173.2M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$1.4B
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| SSAB Biotherapeutics, Inc. | Series B | $175M | Jul 2025 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Shoreline Biosciences | Series B | $43M | Apr 2021 |
| OOruka Therapeutics | Growth | $275M | — |
Top Co-Investors
Logos Capital2 shared
Fairmount2 shared
RTW Investments2 shared
Deep Track Capital2 shared
Perceptive Advisors2 shared
Braidwell LP2 shared
Cormorant Asset Management1 shared
Janus Henderson Investors1 shared
Kite, a Gilead Company1 shared
Wedbush Healthcare Partners1 shared
Sanofi Ventures1 shared
RA Capital Management1 shared
Vivo Capital1 shared
Woodline Partners1 shared
Access Biotechnology1 shared
Avidity Partners1 shared
Redmile Group1 shared
Wellington Management1 shared
BVF Partners LP1 shared
Last updated: 10 April 2026